{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:07:42Z","timestamp":1793311662158,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114058","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T11:34:58Z","timestamp":1639740898000},"page":"114058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway"],"prefix":"10.1016","volume":"229","author":[{"given":"Qingqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-3838","authenticated-orcid":false,"given":"Shaohua","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114058_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114058_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.114058_bib3","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.114058_bib4","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.114058_bib5","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/acs.jmedchem.1c00136","article-title":"Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer","volume":"64","author":"Ren","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cmdc.202000854","article-title":"Novel pyridine-based hydroxamates and 2\u2019-aminoanilides as histone deacetylase inhibitors: biochemical profile and anticancer activity","volume":"16","author":"Zwergel","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.114058_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.114058_bib8","first-page":"664","article-title":"Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to hdac inhibitors in\u00a0vitro","volume":"6","author":"Lutz","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114058_bib9","first-page":"65","article-title":"Inhibition of angiogenesis by hdac inhibitor zyj-34c in\u00a0vitro","volume":"34","author":"Jia","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.114058_bib10","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient synthesis and bioevaluation of novel dual tubulin\/histone deacetylase 3 inhibitors as potential anticancer agents","volume":"64","author":"Peng","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.biocel.2008.09.002","article-title":"New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations","volume":"41","author":"Mai","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114058_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitorbased therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2021.114058_bib14","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1021\/jm4001659","article-title":"Development and therapeutic implications of selective histone deacetylase 6 inhibitors","volume":"56","author":"Kalin","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib15","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.5b00545","article-title":"Potent and selective inhibitors of histone deacetylase-3 containing chiral oxazoline capping groups and a N-(2-Aminophenyl)-benzamide binding unit","volume":"58","author":"Marson","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1039\/C4MD00350K","article-title":"Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment","volume":"5","author":"Pan","year":"2014","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2021.114058_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2021.114058_bib20","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/anie.201915896","article-title":"Potent dual BET\/HDAC inhibitors for efficient treatment of pancreatic cancer","volume":"59","author":"He","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2021.114058_bib21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4155\/fmc-2019-0168","article-title":"Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors","volume":"11","author":"Liang","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114058_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CAD.0000000000000040","article-title":"Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors","volume":"25","author":"Slingerland","year":"2014","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2021.114058_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A\u00a0phase II study of depsipeptide in refractory metastatic renal cell cancer","volume":"5","author":"Stadler","year":"2006","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejmech.2021.114058_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","article-title":"Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer","volume":"48","author":"Haigentz","year":"2012","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib28","first-page":"475641","article-title":"Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors","volume":"2011","author":"Federico","year":"2011","journal-title":"J.\u00a0Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.114058_bib29","first-page":"1705","article-title":"Synergistic effects of suberoylanilide hydroxamic acid combined with cispiatin causing cell cycle arrest independent apoptosis in platinumresistant ovarian cancer cells","volume":"40","author":"Ong","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib30","first-page":"3027","article-title":"In\u00a0vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer","volume":"29","author":"Kim","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2021.114058_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/187152009787047707","article-title":"Radiosensitizing potential of epigenetic anticancer drugs","volume":"9","author":"De Schutter","year":"2009","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib32","first-page":"187","article-title":"The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells","volume":"3","author":"Zhu","year":"2003","journal-title":"Curr. Med. Chem. Anti Cancer Agents"},{"key":"10.1016\/j.ejmech.2021.114058_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2021.114058_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/med.21600","article-title":"Epigenetic polypharmacology: a new frontier for epi-drug discovery","volume":"40","author":"Tomaselli","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.114058_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cbpa.2019.03.002","article-title":"Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer","volume":"50","author":"Stazi","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.114058_bib36","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","author":"Liang","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012996","article-title":"Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents","volume":"5","author":"Peltonen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114058_bib38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cell.2007.02.022","article-title":"Wild-type p53: tumors can't stand it","volume":"128","author":"Kastan","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.114058_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.114058_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114058_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2021.114058_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumours to evaluate clinical outcome","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2021.114058_bib43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CCO.0b013e3282f31d6f","article-title":"Restoration of p53 to limit tumor growth","volume":"20","author":"Wang","year":"2008","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejmech.2021.114058_bib44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature09535","article-title":"Stage-specific sensitivity to p53 restoration during lung cancer progression","volume":"468","author":"Feldser","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114058_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/carcin\/bgl214","article-title":"p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?","volume":"28","author":"Levesque","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2021.114058_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","article-title":"Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells","volume":"153","author":"Condorelli","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114058_bib47","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib48","doi-asserted-by":"crossref","first-page":"7245","DOI":"10.1021\/acs.jmedchem.8b00664","article-title":"Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents","volume":"61","author":"He","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib49","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1021\/acs.jmedchem.6b01769","article-title":"Phthalazino[1,2-b]quinazolinones as p53 activators: cell cycle arrest, apoptotic response and bak-bcl-xl complex reorganization in bladder cancer cells","volume":"60","author":"Zhang","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib50","doi-asserted-by":"crossref","first-page":"112424","DOI":"10.1016\/j.ejmech.2020.112424","article-title":"Discovery of coumarin derivatives as potent and selective cyclindependent kinase 9 (CDK9) inhibitors with high antitumour activity","volume":"200","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib51","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2021.114058_bib52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2019.01.004","article-title":"Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: privileged structure-based design, synthesis, and bioactive evaluation in\u00a0vitro and in\u00a0vivo","volume":"165","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib53","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1021\/acs.jmedchem.8b00384","article-title":"Discovery of novel pazopanib-based HDAC and VEGFR dual inhibitors targeting cancer epigenetics and angiogenesis simultaneously","volume":"61","author":"Zang","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114058_bib54","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00262-020-02697-3","article-title":"The introduction of immunosuppressor (TDO inhibitor) significantly improved the efficacy of irinotecan in treating hepatocellular carcinoma","volume":"70","author":"Liu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2021.114058_bib55","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1021\/acs.jmedchem.7b00467","article-title":"Small molecule inhibitors simultaneously targeting cancer metabolism and epigenetics: discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC) Dual Inhibitors","volume":"60","author":"Dong","year":"2017","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:08Z","timestamp":1759329248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":55,"alternative-id":["S0223523421009077"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114058","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114058"}}